Analysts’ Opinions Are Mixed on These Healthcare Stocks: Teladoc (NYSE: TDOC), Flexion Therapeutics (NASDAQ: FLXN) and Vertex Pharmaceuticals (NASDAQ: VRTX)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Teladoc (TDOCResearch Report), Flexion Therapeutics (FLXNResearch Report) and Vertex Pharmaceuticals (VRTXResearch Report).

Teladoc (TDOC)

In a report issued on June 11, Sean Dodge from RBC Capital maintained a Buy rating on Teladoc, with a price target of $200.00. The company’s shares closed last Friday at $172.27.

According to TipRanks.com, Dodge is a 1-star analyst with an average return of -1.3% and a 45.8% success rate. Dodge covers the Technology sector, focusing on stocks such as Tabula Rasa HealthCare, NextGen Healthcare, and Change Healthcare.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Teladoc with a $177.59 average price target, implying a 0.1% upside from current levels. In a report issued on June 5, Piper Sandler also maintained a Buy rating on the stock with a $220.00 price target.

See today’s analyst top recommended stocks >>

Flexion Therapeutics (FLXN)

In a report issued on June 11, Randall Stanicky from RBC Capital maintained a Buy rating on Flexion Therapeutics, with a price target of $18.00. The company’s shares closed last Friday at $11.25.

According to TipRanks.com, Stanicky ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -10.6% and a 27.1% success rate. Stanicky covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries, Osmotica Pharmaceuticals, and Pacira Pharmaceuticals.

Flexion Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $22.60, a 99.1% upside from current levels. In a report issued on June 2, Northland Securities also assigned a Buy rating to the stock with a $35.00 price target.

Vertex Pharmaceuticals (VRTX)

RBC Capital analyst Brian Abrahams maintained a Hold rating on Vertex Pharmaceuticals on June 12 and set a price target of $260.00. The company’s shares closed last Friday at $268.56.

According to TipRanks.com, Abrahams is a 5-star analyst with an average return of 11.9% and a 54.7% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals, Proteostasis Therapeutics, and Intra-Cellular Therapies.

Vertex Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $289.71.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.